1Evers S. The new IHS classification. Background and structure. Schmerz, 2004, 18 : 351 - 356.
2Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17 : 1 - 12.
3Chen LC, Ashcroft DM. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache, 2007, 47 : 1169-1177.
4Ashcroft DM, Millson D. Naratriptan for the treatment of acute migraine: meta-analysis of randomis- ed controlled trials. Pharmacoepidemiol Drug Saf, 2004, 13 : 73 - 82.
5Chen LC, Ashcroft DM. Meta-analysis of the effic- acy and safety of zolmitriptan in the acute treatment of migraine. Headache, 2008, 48 : 236 - 247.
6Ferrari MD, Loder E, McCarroll KA, et al. Metaanalysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia, 2001, 21 : 129 136.
7Linder SL, Mathew NT, Cady RK, et al. Efficacy and tolerability of almotriptan in adolescents: a ra- ndomized, double-blind, placebo-controlled trial. Headache, 2008, 48 : 1326 - 1336.
8Winner R Rothner AD, Saper J, et al. A randomiz- ed, double-blind, placebo-controlled study of su- matriptan nasal spray in the treatment of acute mig- raine in adolescents. Pediatrics, 2000, 106 : 989-997.
9Winner P, Rothner AD, Wooten JD, et al. Sumatriptan nasal spray in adolescent migraineurs: a rando- mized, double-blind, placebo-controlled, acute stu- dy. Headache, 2006, 46 : 212 - 222.
10Winner P, Lewis D, Visser WH, et al. Rizatriptan 5 mg for the acute treatment of migraine in adole- scents: a randomized, double-blind, placebo-cont- rolled study. Headache, 2002, 42 : 49 - 55.
